Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $8.0 million.

  • Maravai Lifesciences Holdings' Accounts Payables fell 1575.73% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 1575.73%. This contributed to the annual value of $12.0 million for FY2024, which is 1144.56% up from last year.
  • Maravai Lifesciences Holdings' Accounts Payables amounted to $8.0 million in Q3 2025, which was down 1575.73% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Accounts Payables ranged from a high of $718.2 million in Q4 2022 and a low of $4.8 million during Q1 2023
  • Its 5-year average for Accounts Payables is $118.0 million, with a median of $10.4 million in 2022.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Accounts Payables skyrocketed by 870794.7% in 2022 and then plummeted by 9860.05% in 2024.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Accounts Payables stood at $8.2 million in 2021, then skyrocketed by 8707.95% to $718.2 million in 2022, then crashed by 98.51% to $10.7 million in 2023, then rose by 11.45% to $12.0 million in 2024, then tumbled by 33.11% to $8.0 million in 2025.
  • Its Accounts Payables stands at $8.0 million for Q3 2025, versus $11.5 million for Q2 2025 and $9.5 million for Q1 2025.